Results 131 to 140 of about 19,015 (246)

The Voice of a Disease: Why Food Noise Can No Longer Be Ignored!

Obesity, EarlyView.
Abdulhameed Alhazmi, Carel W. le Roux
wiley   +1 more source

Effectiveness and adherence in a tirzepatide‐supported digital weight‐loss programme in Australia: A real‐world observational study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Obesity is a growing global health crisis; pharmacotherapies such as tirzepatide combined with multidisciplinary lifestyle support have shown promise but real‐world evidence in digital weight‐loss services (DWLSs) is limited. This retrospective study evaluated 6‐ and 12‐month weight loss, adherence and predictors of outcomes in an ...
Louis Talay, Jason Hom, Tamara Scott, Neera Ahuja   +3 more
wiley   +1 more source

Semaglutide, a glucagon-like peptide-1 receptor agonist, inhibits oral squamous cell carcinoma growth through P38 MAPK signaling pathway

Journal of Cancer Research and Clinical Oncology
Aims Researches have shown that diabetes mellitus (DM) can promote the risk and progression of oral squamous cell carcinoma (OSCC). Semaglutide, a glucagon-like peptide-1 receptor agonist, is currently employed to treat type 2 diabetes mellitus (T2DM ...
Can Wang, Zhengzheng Wu, Jiaying Zhou, Bin Cheng, Yulei Huang   +4 more
doaj   +1 more source

Az antidiabetikumok kardiovaszkuláris szerepe a véletlen besorolásos vizsgálatokban és az újabb ajánlások világában = Cardiovascular role of novel antidiabetics in randomized controlled trials and newer recommendations [PDF]

, 2017
Bajnok, László
core   +1 more source

Efficacy and safety of once‐weekly insulins in type 2 diabetes: A systematic review and meta‐analysis

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Once‐weekly (OW) insulins represent a promising strategy to reduce injection burden and improve adherence in type 2 diabetes management. This meta‐analysis aimed to quantify pooled effect sizes for key biological and clinical outcomes, integrating new findings from the five large trials published in 2025.
Olivier Bourron, Damien Denimal
wiley   +1 more source

Risk stratification using coronary artery calcium and potential benefit of semaglutide therapy: A cost‐effectiveness modelling study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim Coronary artery calcium (CAC) scoring is observed to improve risk stratification for major adverse cardiovascular events (MACE). Semaglutide, a recently introduced anti‐obesity drug, is very effective, but wider use is limited due to high costs.
Sai Rahul Ponnana, Tong Zhang, Santosh Kumar Sirasapalli, Zhuo Chen, Jean‐Eudes Dazard, Niketh Surya, Shamsa Elhussain, Kanimozhi Sivanantham, Robert Okyere, Ian J. Neeland, Sanjay Rajagopalan, Salil V. Deo   +11 more
wiley   +1 more source

Association of semaglutide treatment with coronary artery inflammation in type 2 diabetes mellitus patients: a retrospective study based on pericoronary adipose tissue attenuation

Cardiovascular Diabetology
Background The pericoronary fat attenuation index (FAI) has emerged as a novel and sensitive biomarker reflecting the degree of coronary artery inflammation.
Yanhong Li, Wenjing Yao, Tianxing Wang, Qian Yang, Kexin Song, Feifei Zhang, Fan Wang, Yi Dang   +7 more
doaj   +1 more source

A treat‐to‐target approach for obesity management: A post hoc analysis of the SURMOUNT‐5 trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Introduction With new advancements in obesity medicine, clarity on goals and expectations for successful disease management is limited. This post hoc analysis assessed application of proposed treat‐to‐target (TtT) thresholds for obesity to the outcome measures of SURMOUNT‐5, which randomised participants with obesity to tirzepatide or ...
Carel W. le Roux, Luca Busetto, Louis Aronne, Deborah Bade Horn, Georgios K. Dimitriadis, Beverly Falcon, Luis‐Emilio Garcia‐Perez, Elisa Gomez Valderas, Theresa Hunter Gibble, Cagri Senyucel, Julia P. Dunn   +10 more
wiley   +1 more source

Providing holistic care for patients with metabolic dysfunction‐associated steatotic liver disease/metabolic dysfunction‐associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and interventions

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Metabolic dysfunction‐associated steatotic liver disease (MASLD), characterised by hepatic steatosis and metabolic dysfunction (i.e., obesity, type 2 diabetes, dyslipidaemia, and hypertension), is affecting over 30% of the adult population worldwide.
Lanlan Chen, Paul Horn, Frank Tacke
wiley   +1 more source

Real‐world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes: A multi‐site retrospective study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Despite the established efficacy of tirzepatide in randomised controlled trials, real‐world effectiveness data in Japanese patients remain limited. This study evaluated the real‐world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes over 52 weeks.
Yusuke Minakata, Masaki Miura, Nobuhiro Nakatake, Masahiro Masuzawa   +3 more
wiley   +1 more source